AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection
Published: 16 November 2023
-
Views:
2171
-
Likes:
7
-
Views:
2171
-
Likes:
7
-
Up Next -
9m 14sPart 1 | Session 8 An Extended Duration Short-Interfering RNA Targeting Lp(a) -
11m 15sPart 1 | Session 9 ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin -
15m 26sPart 1 | Session 10 ARIES HM3: Avoidance of Aspirin with LVAD Devices
-
14m 58sPart 1 | Session 1 ORBITA-2: PCI for Stable Angina Rasha Al-Lamee, Nazli Okumus, Christopher Rajkumar
-
11m 47sPart 1 | Session 2 SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients A Michael Lincoff , Ahmed Ghoneem
-
16m 5sPart 1 | Session 3 MINT: Myocardial Ischaemia & Transfusion Nazli Okumus, Jeffrey L Carson
-
11m 41sPart 1 | Session 4 KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension George L Bakris, Sukriti Banthiya
-
8m 35sPart 1 | Session 5 CordiO App: Speech Analysis to Detect Worsening HF in ADHF Patients Hanad Bashir, William T Abraham
-
14m 32sPart 1 | Session 6 AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health Ramy Doss, Chiadi Ndumele
Overview
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.
These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
More from this programme
Part 1
Radcliffe & Cardionerds @AHA23
About the episode
AHA 23 - Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews Dr Christian Ruff (Brigham and Women's Hospital, US) on the late-breaking findings from the AZALEA-TIMI 71 randomized trial (Anthos Theraputics, Inc).
AZALEA-TIMI 71 aimed to evaluate the bleeding profile of abelcimab as compared to rivaroxaban in patients with atrial fibrillation who are at moderate to high risk of stroke. 1200 patients were enrolled in the trial, who were randomized to receive either the experimental group, or the active comparator group. The experimental arm was split into two treatment groups, where one group received a middle dose of abelcimab, and another received a high dose, both administered subcutaneously once per month. In the active comparator group, 20mg rivaroxaban was taken once per day.
Results showed a potent inhibition of factor XI, with over 95% inhibition over the dosing interval. A ≥2/3 reduction in bleeding as compared to rivaroxaban was observed in patients treated with abelcimab, with reduced major or clinically relevant non-major bleeding, major bleeding and major GI bleeding.
Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.
Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
Faculty Biographies
Naima Maqsood
Naima Maqsood is a cardiology fellow at Temple University Hospital, Philadelphia. She graduated from the Aga Khan University Medical College in Pakistan. She completed Internal Medicine residency at Temple where she was part of the Medical Education Track. Her passions include electrophysiology, hemodynamics, exercise physiology and Medical Education. She is keen on pursuing a career in Cardiac Electrophysiology. Outside the hospital, she enjoys watching horror movies, learning about astrophysics and stargazing.
Christian Ruff
Dr. Christian Thomas Ruff, MD, MPH serves as the Director of the Genetics Core Laboratory and holds the position of Assistant Professor of Medicine at Harvard Medical School, based at Brigham and Women’s Faulkner Hospital in Boston, Massachusetts.
With a diverse educational background, Dr. Ruff graduated from Harvard University with a degree in Neurobiology before earning his medical degree at Johns Hopkins University School of Medicine. His professional journey includes a pivotal role as the Director of General Cardiology at Brigham and Women’s Hospital.
As an esteemed investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Dr. Ruff's expertise spans various facets of cardiology. He serves as the Director of the Genetics Core Laboratory and holds the role of Co-Director of the Clinical Events Committee. Dr. Ruff's specific focus lies in atrial fibrillation, risk stratification, and the implementation of antithrombotic therapy for stroke prevention…
Comments